Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5732)
All Articles published online
|
Publishing Process of This Article
|
Oct 24, 2019 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol 2019; 10(10): 350-357 [PMID: 31799150 DOI: 10.5306/wjco.v10.i10.350] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v10/i10/350.htm |
| Number | Citing Articles |
| 1 |
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 89 doi: 10.1016/j.rgmxen.2023.11.001
|
| 2 |
Maria Paparoupa, Sophie Stupperich, Lisa Goerg-Reifenberg, Andreas Wittig, Frank Schuppert. Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma. Case Reports in Gastroenterology 2020; 14(3): 554 doi: 10.1159/000511252
|
| 3 |
J. Jochmann, A. Fink, A. Stella, R. Feldmann, L. Kramer, C. Posch. Prevention of severe immune‐related colitis caused by combined immune checkpoint inhibition using vedolizumab: A case report. Journal of the European Academy of Dermatology and Venereology 2023; 37(7) doi: 10.1111/jdv.19028
|
| 4 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología (English Edition) 2024; 47(4): 401 doi: 10.1016/j.gastre.2023.10.003
|
| 5 |
Alba GUGLIELMO, Clara BERTUZZI, Eleonora SCAIOLI, Andrea BELLUZZI, Elena SABATTINI, Annalisa PATRIZI, Alessandro PILERI. Iatrogenic Kaposi sarcoma during tumor necrosis factor alpha inhibitors. Italian Journal of Dermatology and Venereology 2021; 156(1) doi: 10.23736/S2784-8671.20.06595-5
|
| 6 |
Anca Macovei Oprescu, Raluca Tulin, Iulian Slavu, Dana Paula Venter, Constantin Oprescu. Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist. Cureus 2021; doi: 10.7759/cureus.19945
|
| 7 |
Ayaka Kaneoka, Etsuko Okada, Hitomi Sugino, Natsuko Saito-Sasaki, Daisuke Omoto, Motonobu Nakamura. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics 2022; 12(2): 480 doi: 10.3390/diagnostics12020480
|
| 8 |
Sae Ohwada, Keisuke Ishigami, Noriyuki Akutsu, Hiroshi Nakase. Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines 2022; 10(6): 1334 doi: 10.3390/biomedicines10061334
|
| 9 |
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Revista Española de Enfermedades Digestivas 2024; doi: 10.17235/reed.2024.10250/2024
|
| 10 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología 2024; 47(4): 401 doi: 10.1016/j.gastrohep.2023.10.009
|
| 11 |
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo. Revista de Gastroenterología de México 2024; 89(1): 89 doi: 10.1016/j.rgmx.2023.11.001
|
| 12 |
Hikaru Ishihara, Tatsuyuki Watanabe, Shinsuke Kumei, Keiichiro Kume, Ichiro Yoshikawa, Masaru Harada. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte–monocyte apheresis combination therapy. Clinical Journal of Gastroenterology 2024; 17(1): 46 doi: 10.1007/s12328-023-01887-7
|